AptarGroup reported third‑quarter 2025 results for the period ended September 30, 2025, with net income of $127.9 million and earnings per share of $1.92. Adjusted earnings per share, excluding one‑time gains and costs, were $1.62, up 4% from the prior year’s $1.56. Revenue rose 6% year‑over‑year to $961.1 million, surpassing analyst estimates.
The company’s three core segments contributed $445.4 million in net sales from Pharma, $327.8 million from Beauty, and $188.0 million from Closures. Pharma sales increased 6%, driven by an 18% jump in the injectables division, while the Closures segment also added to overall growth.
Operating income for the quarter was $136.9 million, slightly lower than the $138.3 million reported in Q3 2024, largely due to higher operating costs. A $26.5 million gain from the remeasurement of an equity‑method investment boosted net income, and the effective tax rate fell to 17.1% from 23.8% in the prior year.
AptarGroup’s management projected fourth‑quarter 2025 earnings per share between $1.20 and $1.28, below the consensus estimate of $1.44. The guidance reflects a less favorable sales mix, lower emergency‑use dispensing system sales, and an expected 35% decline in emergency medicine revenue in 2026.
During the quarter, the company returned $70 million to shareholders through share repurchases and dividends.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.